On November 9, 2021 Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, reported a corporate update in conjunction with the Company’s 10-Q filing for the quarter ended September 30, 2021 (Press release, Foghorn Therapeutics, NOV 9, 2021, View Source [SID1234595041]). With an initial focus in oncology, Foghorn’s Gene Traffic Control Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the third quarter of 2021, we continued to advance our robust pipeline targeting the chromatin regulatory system," said Adrian Gottschalk, President and Chief Executive Officer. "In August, we dosed the first patient in the phase 1 study of FHD-609, our potent, selective, intravenous, small molecule protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma. We continue to enroll patients in the phase 1 studies of FHD-286, an inhibitor of BRG1/BRM being studied in metastatic uveal melanoma and relapsed or refractory AML and MDS, areas of high unmet medical need. These studies are progressing through dose escalation, and we are pleased with the execution of the enrollment to date and look forward to sharing initial data from these studies in the future."

Continued Mr. Gottschalk, "Beyond these two clinical programs, we continue to expand our deep pipeline of precision therapeutic candidates targeting different aspects of the chromatin regulatory system in cancer, including enzymatic inhibitors, transcription factor disruptors and over eight protein degrader programs such as our BRM-selective degrader, ARID1B degrader and other undisclosed programs."

Recent Corporate Highlights:

Dosed First Patient with FHD-609. In August, Foghorn announced the dosing of the first patient in its first-in-human clinical trial of FHD-609. FHD-609 is a highly potent, selective, intravenous, protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma with the intention to expand into additional indications, including SMARCB1 deleted tumors. Sites for the phase 1 study have been activated and are currently dosing patients. To learn more about this study, please visit ClinicalTrials.gov.
Participation at the 4th Annual Targeted Protein Degradation Conference. In October 2021, Foghorn presented at the 4th Annual Targeted Protein Degradation Conference providing an overview of the Company’s degrader capabilities and its phase 1 asset FHD-609, including the programs compelling in-vitro and in-vivo profile supporting first-in-human studies. Within Foghorn’s degrader platform, the Company is actively advancing more than eight targeted protein degrader programs including its BRM-selective degrader for BRG1 mutated cancers and its selective ARID1B program for ARID1A mutated cancers which impacts more than 175,000 patients a year. Additional information on the Summit can be found here.
Key Upcoming Milestones:

FHD-286 data. Foghorn expects to have initial data from the Company’s phase 1 studies of FHD-286 in both metastatic uveal melanoma and relapsed/refractory AML and MDS as early as the fourth quarter of 2021.
FHD-609 data. Foghorn expects to have initial data from the Company’s phase 1 study in synovial sarcoma as early as the first half of 2022.
Upcoming Events

4th Annual Evercore ISI HealthCONx Conference, November 30th-December 2nd, 2021
Financial Condition

Foghorn reported cash, cash equivalents and marketable securities of $120.8 million as of September 30, 2021, as compared to $141.3 million as of June 30, 2021, and $185.8 million as of December 31, 2020.